Search results for "toxoid"

showing 10 items of 49 documents

Circadian variations in antigen-specific proliferation of human T lymphocytes and correlation to cortisol production.

1995

Cortisol is a well-known immunosuppressant when used therapeutically. The present investigation was set out to study if diurnal variations in endogenous cortisol production are reflected by changes in proliferative responses of human lymphocytes to either a mitogen (phytohemagglutinin-A, PHA) or an antigen (tetanus toxoid, TT) stimulus. The study included eight healthy volunteers. Blood was withdrawn at 0200, 0600, 1000, and 1800h for preparation of lymphocytes and determination of cortisol in plasma. Isolated cells were incubated without (baseline activity) or with inclusion of either 1 micrograms PHA or 10 micrograms TT. Proliferation was measured by labelling with 3H-thymidine for 16 h o…

AdultMalemedicine.medical_specialtyCellular immunityHydrocortisoneEndocrinology Diabetes and MetabolismT-LymphocytesEndogenyBiologyLymphocyte ActivationEndocrinologyImmune systemAntigenInternal medicinemedicineTetanus ToxoidHumansCircadian rhythmLymphocyte CountPhytohemagglutininsBiological PsychiatryHydrocortisoneEndocrine and Autonomic SystemsT lymphocyteCircadian RhythmPsychiatry and Mental healthEndocrinologyFemaleMitogensGlucocorticoidmedicine.drugPsychoneuroendocrinology
researchProduct

Antibody Induction Directed against the Tumor-Associated MUC4 Glycoprotein

2015

Mucin glycoproteins are important diagnostic and therapeutic targets for cancer treatment. Although several strategies have been developed to explore anti-tumor vaccines based on MUC1 glycopeptides, only few studies have focused on vaccines directed against the tumor-associated MUC4 glycoprotein. MUC4 is an important tumor marker overexpressed in lung cancer and uniquely expressed in pancreatic ductual adenocarcinoma. The aberrant glycosylation of MUC4 in tumor cells results in an exposure of its peptide backbone and the formation of tumor-associated glycopeptide antigens. Due to the low immunogenicity of these endogenous structures, their conjugation with immune stimulating peptide or prot…

Antibodies NeoplasmMolecular Sequence DataCancer VaccinesBiochemistryEpitopeEpitopesMiceAntigenAntibody SpecificityCell Line TumorTetanus ToxoidAnimalsHumansAmino Acid SequenceMolecular BiologyMUC1chemistry.chemical_classificationMice Inbred BALB CMucin-4biologyImmune SeraImmunogenicityVaccinationOrganic ChemistryToxoidGlycopeptidePancreatic NeoplasmschemistryTandem Repeat SequencesImmunologybiology.proteinMolecular MedicineFemalesense organsAntibodyGlycoproteinChemBioChem
researchProduct

Synthetic Antitumor Vaccines from Tetanus Toxoid Conjugates of MUC1 Glycopeptides with the Thomsen-Friedenreich Antigen and a Fluorine-Substituted An…

2010

Breast NeoplasmsCancer VaccinesAntibodiesCatalysisMiceCell Line TumorTetanus ToxoidmedicineAnimalsHumansAntigens Tumor-Associated CarbohydrateMUC1Vaccines SyntheticThomsen-Friedenreich AntigenChemistryTetanusMucin-1GlycopeptidesToxoidFluorineGeneral ChemistryFlow Cytometrymedicine.diseaseGlycopeptideBiochemistryFemaleConjugateAngewandte Chemie International Edition
researchProduct

Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived…

2000

Abstract Dendritic cell (DC) vaccination, albeit still in an early stage, is a promising strategy to induce immunity to cancer. We explored whether DC can expand Ag-specific CD8+ T cells even in far-advanced stage IV melanoma patients. We found that three to five biweekly vaccinations of mature, monocyte-derived DC (three vaccinations of 6 × 106 s.c. followed by two i.v. ones of 6 and 12 × 106, respectively) pulsed with Mage-3A2.1 tumor and influenza matrix A2.1-positive control peptides as well as the recall Ag tetanus toxoid (in three of eight patients) generated in all eight patients Ag-specific effector CD8+ T cells that were detectable in blood directly ex vivo. This is the first time …

CD4-Positive T-LymphocytesCytotoxicity Immunologicmedicine.medical_treatmentInjections SubcutaneousImmunologyImmunization SecondaryEpitopes T-LymphocyteCD8-Positive T-LymphocytesLymphocyte ActivationCancer VaccinesMonocytesViral Matrix ProteinsAntigens NeoplasmTetanus ToxoidImmunology and AllergyMedicineCytotoxic T cellHumansMelanomaCells Culturedbusiness.industryMelanomaToxoidCell DifferentiationDendritic cellDendritic Cellsmedicine.diseaseNeoplasm ProteinsImmunizationImmunologyInjections IntravenousIntercellular Signaling Peptides and ProteinsbusinessPeptidesAdjuvantCD8Ex vivoT-Lymphocytes Cytotoxic
researchProduct

Remission of experimental autoimmune hepatitis is associated with antigen-specific and non-specific immunosuppression.

1993

SUMMARY Experimental autoimmune hepatitis (EAH) is an animal model for autoimmune hepatitis. The disease is T cell-mediated and runs a subacute course, with maximal disease activity around week four after disease induction and a slow ensuing recovery. The aim of the present study was to investigate the immunoregulatory mechanisms that may account for recovery in EAH. It was found that T cell reactivity to liver antigens preceded histological disease, but at the peak of disease activity this T cell response was already suppressed. Active and antigen-specific suppression could be demonstrated, as irradiated splenocytes from animals at the beginning of recovery from EAH were able to suppress i…

Cellular immunitymedicine.medical_treatmentT-LymphocytesImmunologyAutoimmune hepatitisBiologyHepatitis AnimalAutoimmune DiseasesMiceImmune systemAntigenmedicineImmune ToleranceTetanus ToxoidImmunology and AllergyAnimalsAntigensAutoimmune diseaseHepatitisMice Inbred BALB CImmunosuppressionT lymphocytemedicine.diseaseMice Inbred C57BLImmunologyFemaleResearch Article
researchProduct

The development of synthetic antitumour vaccines from mucin glycopeptide antigens.

2013

Based on important cell-biological and biochemical results concerning the structural difference between membrane glycoproteins of normal epithelial cells and epithelial tumour cells, tumour-associated glycopeptide antigens have been chemically synthesised and structurally confirmed. Glycopeptide structures of the tandem repeat sequence of mucin MUC1 of epithelial tumour cells constitute the most promising tumour-associated antigens. In order to generate a sufficient immunogenicity of these endogenous structures, usually tolerated by the immune system, these synthetic glycopeptide antigens were conjugated to immune stimulating components: in fully synthetic two-component vaccines either with…

DendrimersVaccines SyntheticChemistryImmunogenicityT-LymphocytesMucin-1ToxoidGeneral ChemistryCancer VaccinesEpitopeGlycopeptideAntibodiesImmune systemEpitope mappingAntigenNeoplasmsImmunologyTetanus ToxoidAnimalsHumansMUC1Epitope MappingChemical Society reviews
researchProduct

Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.

2011

Conjugate vaccines using diphtheria toxoid variant (CRM(197)), diphtheria toxoid and tetanus toxoid (TT) as carrier protein may induce immune interactions (interference or impairment as measured by lower antibody levels, or enhancement [higher antibody levels]) when coadministered with other vaccines. Immune enhancement occurs when two TT conjugates are coadministered. CRM(197) conjugate vaccines induce immune bystander interference when given with diphtheria-tetanus-acellular pertussis vaccines, which reduces responses to coadministered Haemophilus influenzae type b vaccine conjugated to TT. These bystander effects are greater as the amount of CRM(197) administered increases. When large am…

Diphtheria ToxoidImmunologyMeningococcal vaccinecomplex mixturesImmune systemAdjuvants ImmunologicBacterial ProteinsDrug DiscoverymedicineBystander effectTetanus ToxoidHumansDrug InteractionsImmunization SchedulePharmacologyDiphtheria toxinDrug CarriersVaccines ConjugateTetanusbusiness.industryToxoidmedicine.diseaseVirologyVaccinationPneumococcal vaccineImmunologyBacterial VaccinesMolecular MedicinebusinessExpert review of vaccines
researchProduct

The modulation of immune complex aggregation by classical pathway-mediated reactions.

1985

Abstract Classical pathway (CP)-triggered reactions of complement-modulated immune complex(IC) aggregation (tetanus toxoid/human anti-tetanus toxoid-IgG; ICs of equivalence) were investigated turbidimetrically during the early stages of reaction. Monospecific Fab'- or Fab-fragments (rabbit) directed against certain complement components were used to block the complement function in normal human serum (NHS). Additionally, parts of the reactions were studied using purified complement components. C1q in serum generated by the addition of EDTA as well as purified C1q were found to increase the IC aggregation. In contrast to C1q, macromolecular C1 is able to inhibit IC aggregation, whereas addit…

EffectorChemistryComplement Activating EnzymesComplement C1qImmunologyToxoidHematologyAntigen-Antibody ComplexComplement System ProteinsComplement C1 Inactivator ProteinsImmune complexComplement componentsComplement (complexity)Classical complement pathwayBiochemistrySolubilityComplement C1ImmunologyImmunology and AllergyHumansComplement Pathway ClassicalComplement ActivationFunction (biology)MacromoleculeImmunobiology
researchProduct

Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxic…

2012

Glycopeptides of tumor-associated mucin MUC1 are promising target structures for the development of antitumor vaccines. Because these endogenous structures were weakly immunogenic, they were coupled to immune-response-stimulating T-cell epitopes and the Pam(3)Cys lipopeptide to induce strong immune responses in mice. A new thioether-ligation method for the synthesis of two- and three-component vaccines that contain MUC1 glycopeptides as the B-cell epitopes, a T-cell epitope peptide, and the Pam(3)CSK(4) lipopeptide is described. The resulting fully synthetic vaccines were used for the vaccination of mice, either in a liposome with Freund's adjuvant or in aqueous PBS buffer. The three-compon…

Epitopes T-LymphocyteAntineoplastic AgentsSulfidesCancer VaccinesCatalysisEpitopechemistry.chemical_compoundLipopeptidesMiceImmune systemAntigenAdjuvants ImmunologicNeoplasmsAnimalsAntigens Tumor-Associated CarbohydrateAmino Acid SequenceCytotoxicityVaccines SyntheticOrganic ChemistryMucin-1ToxoidGlycopeptidesLipopeptideGeneral ChemistryMolecular biologyComplement-dependent cytotoxicityGlycopeptidechemistryEpitopes B-LymphocyteChemistry (Weinheim an der Bergstrasse, Germany)
researchProduct

Enhanced immunogenicity of multivalent MUC1 glycopeptide antitumour vaccines based on hyperbranched polymers.

2015

Enhancing the immunogenicity of an antitumour vaccine still poses a major challenge. It depends upon the selected antigen and the mode of its presentation. We here describe a fully synthetic antitumour vaccine, which addresses both aspects. For the antigen, a tumour-associated MUC1 glycopeptide as B-cell epitope was synthesised and linked to the immunostimulating T-cell epitope P2 derived from tetanus toxoid. The MUC1-P2 conjugate is presented multivalently on a hyperbranched polyglycerol to the immune system. In comparison to a related vaccine of lower multivalency, this vaccine exposing more antigen structures on the hyperbranched polymer induced significantly stronger immune responses in…

GlycerolPolymersEnzyme-Linked Immunosorbent AssayBiochemistryCancer VaccinesEpitopeMiceImmune systemAntigenAnimalsPhysical and Theoretical ChemistryMUC1Mice Inbred BALB CbiologyMolecular StructureChemistryImmunogenicityOrganic ChemistryMucin-1ToxoidGlycopeptidesVirologyGlycopeptideImmunologybiology.proteinFemaleAntibodyOrganicbiomolecular chemistry
researchProduct